|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MICU3 |
Gene summary for MICU3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MICU3 | Gene ID | 286097 |
| Gene name | mitochondrial calcium uptake family member 3 | |
| Gene Alias | EFHA2 | |
| Cytomap | 8p22 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q86XE3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 286097 | MICU3 | NAFLD1 | Human | Liver | NAFLD | 1.36e-08 | 7.98e-01 | -0.04 |
| 286097 | MICU3 | S41 | Human | Liver | Cirrhotic | 1.33e-06 | 6.32e-01 | -0.0343 |
| 286097 | MICU3 | HCC1_Meng | Human | Liver | HCC | 3.67e-14 | -1.46e-01 | 0.0246 |
| 286097 | MICU3 | HCC2_Meng | Human | Liver | HCC | 3.28e-02 | -1.38e-01 | 0.0107 |
| 286097 | MICU3 | HCC1 | Human | Liver | HCC | 4.30e-05 | 6.51e-01 | 0.5336 |
| 286097 | MICU3 | HTA12-23-1 | Human | Pancreas | PDAC | 6.98e-11 | 8.68e-01 | 0.3405 |
| 286097 | MICU3 | HTA12-25-1 | Human | Pancreas | PDAC | 4.34e-07 | 5.52e-01 | 0.313 |
| 286097 | MICU3 | HTA12-26-1 | Human | Pancreas | PDAC | 2.09e-10 | 6.18e-01 | 0.3728 |
| 286097 | MICU3 | HTA12-29-1 | Human | Pancreas | PDAC | 9.20e-26 | 5.99e-01 | 0.3722 |
| 286097 | MICU3 | male-WTA | Human | Thyroid | PTC | 2.08e-05 | 4.50e-02 | 0.1037 |
| 286097 | MICU3 | PTC01 | Human | Thyroid | PTC | 2.78e-13 | 2.49e-01 | 0.1899 |
| 286097 | MICU3 | PTC04 | Human | Thyroid | PTC | 8.00e-19 | 2.35e-01 | 0.1927 |
| 286097 | MICU3 | PTC05 | Human | Thyroid | PTC | 8.22e-14 | 5.28e-01 | 0.2065 |
| 286097 | MICU3 | PTC06 | Human | Thyroid | PTC | 4.91e-23 | 5.52e-01 | 0.2057 |
| 286097 | MICU3 | PTC07 | Human | Thyroid | PTC | 1.06e-32 | 4.96e-01 | 0.2044 |
| 286097 | MICU3 | ATC12 | Human | Thyroid | ATC | 2.03e-10 | 2.01e-01 | 0.34 |
| 286097 | MICU3 | ATC13 | Human | Thyroid | ATC | 1.27e-14 | 2.24e-01 | 0.34 |
| 286097 | MICU3 | ATC2 | Human | Thyroid | ATC | 1.30e-04 | 3.68e-01 | 0.34 |
| 286097 | MICU3 | ATC3 | Human | Thyroid | ATC | 1.21e-02 | 3.63e-01 | 0.338 |
| 286097 | MICU3 | ATC4 | Human | Thyroid | ATC | 2.25e-08 | 2.55e-01 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00515605 | Liver | NAFLD | mitochondrial calcium ion homeostasis | 8/1882 | 26/18723 | 3.06e-03 | 2.75e-02 | 8 |
| GO:00068397 | Liver | Cirrhotic | mitochondrial transport | 112/4634 | 254/18723 | 1.03e-11 | 6.66e-10 | 112 |
| GO:005156011 | Liver | Cirrhotic | mitochondrial calcium ion homeostasis | 15/4634 | 26/18723 | 3.43e-04 | 2.93e-03 | 15 |
| GO:19905425 | Liver | Cirrhotic | mitochondrial transmembrane transport | 41/4634 | 102/18723 | 4.08e-04 | 3.37e-03 | 41 |
| GO:00364444 | Liver | Cirrhotic | calcium import into the mitochondrion | 8/4634 | 14/18723 | 9.65e-03 | 4.35e-02 | 8 |
| GO:000683912 | Liver | HCC | mitochondrial transport | 184/7958 | 254/18723 | 2.30e-22 | 3.83e-20 | 184 |
| GO:199054212 | Liver | HCC | mitochondrial transmembrane transport | 78/7958 | 102/18723 | 2.73e-12 | 1.26e-10 | 78 |
| GO:003644411 | Liver | HCC | calcium import into the mitochondrion | 13/7958 | 14/18723 | 1.25e-04 | 1.03e-03 | 13 |
| GO:005156021 | Liver | HCC | mitochondrial calcium ion homeostasis | 20/7958 | 26/18723 | 3.82e-04 | 2.61e-03 | 20 |
| GO:00068513 | Liver | HCC | mitochondrial calcium ion transmembrane transport | 16/7958 | 20/18723 | 7.15e-04 | 4.37e-03 | 16 |
| GO:000683928 | Thyroid | PTC | mitochondrial transport | 150/5968 | 254/18723 | 2.76e-19 | 3.34e-17 | 150 |
| GO:199054225 | Thyroid | PTC | mitochondrial transmembrane transport | 57/5968 | 102/18723 | 4.49e-07 | 7.38e-06 | 57 |
| GO:00068515 | Thyroid | PTC | mitochondrial calcium ion transmembrane transport | 16/5968 | 20/18723 | 1.31e-05 | 1.42e-04 | 16 |
| GO:00515608 | Thyroid | PTC | mitochondrial calcium ion homeostasis | 19/5968 | 26/18723 | 1.93e-05 | 1.98e-04 | 19 |
| GO:00364446 | Thyroid | PTC | calcium import into the mitochondrion | 12/5968 | 14/18723 | 4.96e-05 | 4.42e-04 | 12 |
| GO:000683929 | Thyroid | ATC | mitochondrial transport | 151/6293 | 254/18723 | 2.07e-17 | 2.14e-15 | 151 |
| GO:199054226 | Thyroid | ATC | mitochondrial transmembrane transport | 57/6293 | 102/18723 | 3.05e-06 | 3.49e-05 | 57 |
| GO:000685111 | Thyroid | ATC | mitochondrial calcium ion transmembrane transport | 16/6293 | 20/18723 | 2.79e-05 | 2.36e-04 | 16 |
| GO:005156014 | Thyroid | ATC | mitochondrial calcium ion homeostasis | 19/6293 | 26/18723 | 4.49e-05 | 3.61e-04 | 19 |
| GO:003644412 | Thyroid | ATC | calcium import into the mitochondrion | 12/6293 | 14/18723 | 8.96e-05 | 6.59e-04 | 12 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MICU3 | SNV | Missense_Mutation | c.757N>A | p.Asp253Asn | p.D253N | Q86XE3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0SW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD | |
| MICU3 | SNV | Missense_Mutation | c.1072N>C | p.Glu358Gln | p.E358Q | Q86XE3 | protein_coding | tolerated(0.11) | benign(0.036) | TCGA-E2-A14Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| MICU3 | SNV | Missense_Mutation | c.826N>C | p.Asp276His | p.D276H | Q86XE3 | protein_coding | deleterious(0.05) | benign(0.417) | TCGA-E2-A15T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| MICU3 | insertion | Frame_Shift_Ins | novel | c.790_791insA | p.Phe264TyrfsTer6 | p.F264Yfs*6 | Q86XE3 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MICU3 | insertion | Nonsense_Mutation | novel | c.792_793insCTTTGGTATTGGTAACCCATAATTA | p.Arg265LeufsTer5 | p.R265Lfs*5 | Q86XE3 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MICU3 | deletion | Frame_Shift_Del | c.425delN | p.Thr143HisfsTer13 | p.T143Hfs*13 | Q86XE3 | protein_coding | TCGA-D8-A146-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| MICU3 | SNV | Missense_Mutation | rs751018914 | c.838N>T | p.Arg280Cys | p.R280C | Q86XE3 | protein_coding | deleterious(0.03) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MICU3 | SNV | Missense_Mutation | c.1108N>C | p.Glu370Gln | p.E370Q | Q86XE3 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MICU3 | SNV | Missense_Mutation | c.835N>G | p.Lys279Glu | p.K279E | Q86XE3 | protein_coding | deleterious(0.04) | benign(0.046) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MICU3 | SNV | Missense_Mutation | rs201654618 | c.449N>A | p.Arg150His | p.R150H | Q86XE3 | protein_coding | tolerated(0.55) | benign(0.137) | TCGA-MA-AA3Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |